AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 139 filers reported holding AMICUS THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.28 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $3,028,000 | +169.6% | 290,000 | +107.1% | 1.30% | +60.8% |
| Q3 2019 | $1,123,000 | -74.3% | 140,000 | -60.0% | 0.81% | -47.8% |
| Q2 2019 | $4,368,000 | +591.1% | 350,000 | +697.3% | 1.55% | +1205.0% |
| Q4 2017 | $632,000 | -90.7% | 43,900 | -90.3% | 0.12% | -90.2% |
| Q3 2017 | $6,801,000 | +842.0% | 451,000 | +210.4% | 1.22% | +354.9% |
| Q4 2016 | $722,000 | -85.4% | 145,300 | -78.3% | 0.27% | -85.6% |
| Q3 2016 | $4,958,000 | -21.8% | 670,000 | -42.3% | 1.86% | -38.9% |
| Q2 2016 | $6,342,000 | -70.0% | 1,161,545 | -53.5% | 3.05% | -74.2% |
| Q1 2016 | $21,125,000 | +44.9% | 2,500,000 | +66.4% | 11.81% | +69.4% |
| Q4 2015 | $14,576,000 | -25.8% | 1,502,661 | +7.0% | 6.97% | -38.7% |
| Q3 2015 | $19,651,000 | -21.8% | 1,404,667 | -20.9% | 11.38% | -26.7% |
| Q2 2015 | $25,116,000 | +17.5% | 1,775,000 | -9.6% | 15.53% | -13.7% |
| Q1 2015 | $21,374,000 | +57.3% | 1,964,565 | +20.3% | 18.00% | +96.1% |
| Q4 2014 | $13,584,000 | – | 1,632,720 | – | 9.18% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |